Related Experiment Video
Updated: Jul 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Development and evaluation of automated screening algorithms for pre-analytical errors in pharmacokinetic data: a
Minsub Shim1, Jaegu Kang1, Kyung-Sang Yu1
1Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
Automated methods can detect pre-analytical errors in pharmacokinetic data. A Mahalanobis distance-based approach significantly outperformed a run-test method in identifying sample mix-ups, ensuring data integrity.
Area of Science:
- Pharmacokinetics and Pharmacometrics
- Clinical Pharmacology
- Data Quality Assurance
Background:
- Pre-analytical errors, such as sample mix-ups, can severely compromise pharmacokinetic (PK) data integrity.
- Ensuring the accuracy of PK data is crucial for reliable clinical pharmacology research and drug development.
- Existing methods for detecting pre-analytical errors in PK datasets may lack sufficient sensitivity or specificity.
Purpose of the Study:
- To develop and validate automated methods for detecting pre-analytical errors in simulated pharmacokinetic data.
- To compare the performance of a Mahalanobis distance-based method against a traditional run-test method.
- To assess the robustness of these methods under various challenging conditions, including different PK models and data imperfections.
Main Methods:
- Simulated vancomycin PK data were generated and intentionally corrupted with two types of pre-analytical errors: time point swaps (TS) and concentration swaps (CS).
- Two automated detection approaches were developed: a run-test non-parametric method and a Mahalanobis distance-based method employing leave-one-out cross-validation (LOOCV).
- Performance was evaluated on 12,500 simulated PK profiles, comparing error detection rates, specificity, precision, recall, and area under the ROC curve (AUC).
Main Results:
- The Mahalanobis distance-based method demonstrated a significantly higher error detection rate (79.7%) compared to the run-test method (59.6%, p < 0.001).
- The distance-based method achieved a superior AUC (0.856 vs. 0.574) and better recall for TS errors (80.4% vs. 71.9%) and precision for CS errors (86.1% vs. 59.8%).
- Detection performance remained robust across alternative population PK models, a different drug (theophylline), contaminated training sets, missing data, and sampling time variations.
Conclusions:
- The Mahalanobis distance-based method with LOOCV is a more effective tool for identifying pre-analytical errors in PK datasets than the conventional run-test method.
- This distance-based approach offers a practical and reliable quality control solution for enhancing the integrity of pharmacokinetic data in research.
- Implementing such automated detection tools is vital for ensuring the accuracy and validity of findings in clinical pharmacology.
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Preclinical Development: Overview
